Nanobiotix to present at March 2026 investor conferences

Nanobiotix S.A. filed a Form 6-K to share a press release announcing its participation in several investor conferences in March.

Rhea-AI Filing Summary

Nanobiotix S.A. filed a Form 6-K to share a press release announcing its participation in several investor conferences in March. Company management, including CEO Laurent Levy and CFO & Business Officer Bart van Rhijn, will speak at healthcare and biotech events hosted by TD Cowen, UBS, Jefferies, and Leerink in Boston and Miami Beach. These appearances are intended to present the company’s late-stage nanotechnology-based oncology pipeline and broader platform to the investment community and other stakeholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nanobiotix (NBTX) announce in its February 2026 Form 6-K?

Nanobiotix announced management participation in several March 2026 investor conferences. The company will present at healthcare and biotech events hosted by TD Cowen, UBS, Jefferies, and Leerink, highlighting its late-stage nanotechnology oncology programs to investors and industry stakeholders.

Which March 2026 conferences will Nanobiotix (NBTX) attend?

Nanobiotix will attend TD Cowen's Health Care Conference in Boston and three events in Miami Beach: UBS Biotech Summit, Jefferies Biotech on the Beach Summit, and Leerink's Global Healthcare Conference, providing multiple forums to discuss its nanotherapeutic cancer pipeline.

Who will represent Nanobiotix (NBTX) at the March 2026 conferences?

CEO Laurent Levy and Chief Financial & Business Officer Bart van Rhijn will represent Nanobiotix. They are scheduled for fireside chats at TD Cowen’s conference and Leerink’s Global Healthcare Conference, engaging directly with investors about the company’s late-stage clinical programs.

When and where is Nanobiotix (NBTX) presenting at TD Cowen's Health Care Conference?

Nanobiotix will present at TD Cowen's Health Care Conference on Wednesday, March 4, 2026, in Boston. A fireside chat featuring CEO Laurent Levy and CFO & Business Officer Bart van Rhijn is scheduled for 11:10am ET / 5:10pm CET during the event.

What sessions will Nanobiotix (NBTX) hold at Leerink's Global Healthcare Conference?

At Leerink's Global Healthcare Conference on Wednesday, March 11, 2026, in Miami Beach, Nanobiotix will host a fireside chat at 2:20pm EDT / 7:20pm CET. CEO Laurent Levy and CFO & Business Officer Bart van Rhijn will present the company’s nanotherapeutic oncology strategy.

What type of company is Nanobiotix (NBTX) according to the Form 6-K press release?

Nanobiotix is described as a late-stage clinical biotechnology company pioneering disruptive, physics-based nanotherapeutic approaches. Its platforms target oncology, bioavailability and biodistribution, and central nervous system disorders, supported by more than 25 patent families and listings on Euronext Paris and Nasdaq.

Where is Nanobiotix (NBTX) headquartered and what markets is it listed on?

Nanobiotix is headquartered in Paris, France, with subsidiaries including an office in Cambridge, Massachusetts. The company has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020, reflecting its global capital markets presence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On February 25, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated February 25, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: February 25, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

NANOBIOTIX to Participate in Investor Conferences in March

PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March:

TD Cowen's Health Care Conference
Date: Wednesday, March 4, 2026
Location: Boston, MA
Time of the fireside chat: 11:10am ET / 5:10pm CET
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

UBS Biotech Summit Miami
Date: Monday, March 9, 2026
Location: Miami Beach, FL

Jefferies Biotech on the Beach Summit
Date: Tuesday, March 10, 2026
Location: Miami Beach, FL

Leerink's Global Healthcare Conference
Date: Wednesday, March 11, 2026
Location: Miami Beach, FL
Time of the fireside chat: 2:20pm EDT / 7:20pm CET
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

  Attachment

• 2026-02-25 -- NBTX -- Presenting @ March Conferences -- FINAL (https://ml.globenewswire.com/Resource/Download/897f5600-4652-4f63-a9e2-9690182f484e)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.2 KB